








































































oxygen	concentration,	the	hydroxylation	of	the	transcriptional	factor	HIF-1α	(hypoxia	inducible	 factor)	 is	 attenuated	 and	 its	 degradation	 is	 prevented.	 HIF-1α	 is	 then	heterodimerize	with	HIF-1β	 and	 translocate	 to	 the	 nucleus	 to	 bind	 hypoxia	 response	element	(HRE)	in	order	to	transactivate	target	genes	such	as	VEGF	(7).	The	interaction	between	VEGF	ligands	and	receptors	is	essential	for	starting	the	angiogenic	process.			





moderately	diffusible,	as	it	contains	only	one	heparin-binding	domain	encoded	by	exon	7.	The	shortest	isoform,	VEGF-A121,	is	a	diffusible	protein,	as	it	lacks	both	exons	necessary	for	encoding	(HPD)	(12,	13).	Plasmin	cleavage	at	the	COOH	terminus	of	higher	molecular	weight	 isoforms	 results	 in	 highly	 diffusible	 fragments.	 Both	 matrix	 binding	 and	proteolytic	release	regulate	the	spatial	distribution	of	VEGF	in	the	tissue	and	allow	the	formation	 of	 extracellular	 VEGF	 gradients	 to	 stimulate	 endothelial	 growth	 (14).	 The	corresponding	mouse	 isoforms	are	one	amino	acid	shorter:	VEGF-A120,	VEGF-A164,	and	VEGF-A188	(15).	The	importance	of	VEGF	gradients	was	demonstrated	in	vivo	in	a	mouse	retinal	 model,	 where	 VEGF-A164	 and	 VEGF-A188,	 which	 bind	 the	 extracellular	 matrix,	facilitate	 EC	 cell	migration	 through	 the	 establishment	 of	 a	 gradient.	 VEGF-A120,	which	represents	the	diffusible	isoform,	induced	random	endothelial	cell	migration	(16).							 	






angiogenesis	in	most	organs	studied.	Recent	studies	have	demonstrated	that	VEGF-B	is	crucial	for	blood	vessel	survival	rather	than	for	stimulating	angiogenesis	(17,	18).		VEGF-C	 and	 VEGF-D	 are	 synthesized	 as	 a	 preproprotein	 and	 proteolytically	process	to	be	activated.	They	are	known	as	lymphangiogenic	factors,	implicated	in	tumor	angiogenesis	and	metastasis	(19).	Orf	virus,	which	is	a	parapoxivirus,	encodes	VEGF-E	to	induce	angiogenesis	in	virus-infected	lesions.	VEGF-E	has	a	similar	propriety	to	that	of	VEGF165	without	the	heparin-binding	domain	(6,	20).	Among	all	VEGFs,	VEGF-A	and	its	receptors	have	been	shown	to	play	a	major	role	in	angiogenesis,	vascular	permeability,	cell	migration	and	gene	expression.			
























The	 cis	 configuration	 allows	 a	 rapid	 VEGFR-2/NP1	 complex	 formation	 and	internalization	 where	 biding	 in	 trans	 delays	 complex	 formation,	 therefore	 inhibiting	angiogenesis.	 NP1	 therefore	 has	 an	 important	 role	 in	 regulating	 VEGFR	 trafficking	affecting	VEGF	signaling	and	angiogenesis	(29).			
1.2 Cellular	Mechanism	of	Angiogenesis	Angiogenesis	is	the	growth	of	blood	vessels	from	the	existing	vascular	bed.	There	are	two	main	 cellular	mechanisms:	 sprouting,	 and	 intussusceptive	angiogenesis.	Both	occur	 in	utero	and	in	adults.	As	its	name	suggests,	sprouting	angiogenesis	involves	the	formation	of	 endothelial	 sprouts	 that	 grow	 towards	 an	 angiogenic	 gradient.	 In	 contrast,	intussusceptive	angiogenesis	is	called	splitting	angiogenesis	because	an	existing	vessel	splits	into	two	new	ones	(40).		





Tip	cells	are	endothelial	cells	with	migratory	capacity	characterized	by	numerous	filopodia	extensions	to	sense	VEGF	gradient	in	the	surrounding	extracellular	matrix	(Fig.	4).	In	contrast,	the	neighboring	ECs,	called	stalk	cells,	are	more	proliferative	and	thus	act	as	building	blocks	for	the	nascent	sprout	(41,	43).	VEGF	and	Notch	signaling	pathways	are	responsible	for	the	specification	of	a	tip	and	stalk	cells	in	the	vascular	endothelium	(Fig.	4).	In	mammals,	there	are	four	Notch	receptors	(Notch1-4)	and	five	ligands,	Jagged-1	and	2	and	Delta-like	proteins	(Dll1,	Dll3	and	Dll4).	Notch	receptors	are	large	single-pass	type	I	transmembrane	proteins	and	most	of	the	Notch	ligands	are	also	themselves	type	I	transmembrane	proteins.	Therefore,	Notch	signaling	is	mediated	by	cell-cell	interaction	and	can	happen	in	cis	(in	the	same	cell)	or	in	trans	(different	cells)	(44).	The	interaction	between	Notch	receptors	and	ligands	triggers	a	series	of	proteolytic	cleavages	that	result	in	 the	 release	 of	 the	 active	 Notch	 intracellular	 domain	 (NCID).	 Afterward,	 NCID	translocate	to	the	nucleus,	where	it	activates	the	expression	of	target	genes	(43).											










head’	anastomosis)	or	between	a	tip	cell	sprout	and	a	functional	vessel	(‘Head-to-side’	anastomosis)	 (41).	 Mural	 cells	 are	 then	 recruited	 by	 platelet-derived	 growth	 factor	(PDGF-BB)	 expressed	 by	 endothelial	 cells.	 Mural	 cells	 reduce	 endothelial	 cell	proliferation	 and	 migration.	 The	 establishment	 of	 a	 new	 blood	 flow	 allows	 vessel	remodeling,	which	is	regulated	by	the	shear	stress-responsive	transcription	factor	KLK2.	Autocrine	 signals,	 including	VEGF,	 Angiopoietin-1	 and	Notch	 promote	 endothelial	 cell	quiescence,	thereby	stabilizing	nascent	vessels	(42).			


















The	maturation	of	newly-formed	capillaries	is	a	late	event	in	the	angiogenic	process.	This	process	is	a	crucial	step	in	achieving	a	functional	vascular	network.	It	involves	pericyte	recruitment,	 deposition	 of	 the	 extracellular	 matrix,	 endothelium	 cell	 quiescence	(endothelial	phalanx	phenotype)	and	an	increased	formation	of	cell	junctions	(42).	Active	endothelium	is	easily	susceptible	to	regression	on	withdrawal	of	growth	factors,	whereas	mature	vessels	are	more	resistant	(61).	An	increase	in	blood	flow	and	oxygen	delivery	promotes	 vessel	 maturation	 and	 stabilization.	 Vessel	 maturation	 leads	 to	 vascular	stabilization—a	 state	 in	 which	 newly-induced	 vessels	 are	 provided	 with	 structural	support,	mechanical	resistance	and	reduced	endothelial	cell	demand	for	soluble	survival	factors,	such	as	VEGF	(62).		







2.1.	1	 Pericyte	biology	Pericytes	are	mural	cells	of	 the	microcirculation	which	are	known	to	play	key	roles	in	regulating	microvascular	morphogenesis	 and	 stability	 in	 different	 tissues	 and	 organs	(65).	 Pericytes	were	 first	 described	more	 than	 100	 years	 ago	 by	Benjamin	Rouget	 as	perivascular	 contractile	 cells	 surrounding	 blood	 capillaries	 (66).	 Electron-microscopy	analysis	 helped	 to	 elucidate	 their	 morphology.	 In	 general,	 mature	 pericytes	 are	












2.1.2.1	PDGF	and	PDGFR	Family	During	 vessel	 sprouting,	 activated	 endothelial	 cells	 release	 PDGF-BB	 to	 chemoattract	PDGF	receptor-b+	pericytes	(62).	Platelet-derived	growth	factors	(PDGFs)	are	important	mitogen	 for	many	 types	of	 cells	 of	mesenchymal	 origin,	 including	 fibroblasts,	 smooth	muscle	 cells	 and	 pericytes	 and	 for	 neuroectodermal	 derived	 cells	 including	oligodendrocytes	(74).		The	PDGF	family	is	composed	of	four	polypeptide	chains:	PDGF-A,	PDGF-B,	PDGF-C	and	PDGF-D.	Genes	located	on	chromosomes	7,	22,	4,	and	11	(pdgfa,	pdgfb,	pdgfc	and	











			PDGF	 dimer	 binds	 the	 receptor	 at	 Ig	 domains	 D2	 and	 D3	 and	 promotes	 receptor	dimerization	(homo-	or	heterodimerization),	which	is	then	stabilized	by	direct	receptor-receptor	 interaction	with	 the	D4	and	D5	domains	 (75).	Once	dimerization	occurs,	 the	intracellular	domain	undergoes	autophosphorylation	in	trans	between	the	receptors	in	the	 dimers.	 PDGFRa	 and	 PDGFRb	 have	 10	 and	 11	 autophosphorylation	 sites,	respectively.	The	autophosphorylation	of	certain	tyrosine	kinase	has	two	main	functions:	(I)	it	promotes	receptor	activation	by	conformational	changes	of	the	intracellular	parts,	and	 (II)	 it	 causes	 subsequent	 recruitment	of	 SH-domain-containing	 signaling	 proteins	(81).	 Finally,	 receptor	 activation	 promotes	 cellular	 responses	 like	 proliferation	 and	migration.			





2.1.2.1	PDGF-BB/PDGFRb	signaling	during	blood	vessel	formation	During	 angiogenesis,	 PDGF-BB	 and	 PDGFRb	 play	 an	 important	 role	 in	 pericyte	recruitment	to	newly-induced	blood	vessels.	PDGF-BB	is	release	at	higher	levels	by	tip	cells	 when	 compared	 to	 stalk	 cells.	 Once	 secreted,	 PDGF-BB	 strongly	 binds	 the	extracellular	matrix-forming	steep	gradients,	allowing	a	proper	recruitment	of	pericytes.	As	a	consequence,	pericytes	stabilize	the	nascent	vessels	through	paracrine	signals	(67,	82).	 The	 role	 of	 PDGF-BB/	 PDGFRb	 is	 supported	 by	 several	 knockout	 experiments.	Knockout	of	pdgfb	or	pdgrb	in	mice	is	lethal	at	the	embryonic	stage	due	to	widespread	microvascular	defects	consisting	of	vessel	dilatations,	microaneurisms,	excessive	luminal	folds	and	 lack	of	pericyte	recruitment.	The	 failure	to	recruit	PDGFRb-positive	pericyte	progenitors	leads	to	vascular	instability	and	regression	(70).	Moreover,	deletion	of	the	PDGF-BB	retention	motif	 in	mice	(necessary	 for	pericyte	adhesion)	results	 in	pericyte	detachment	 from	 the	microvessels,	 suggesting	 that	 PDGF-BB	 retention	 is	 an	 absolute	recruitment	for	pericyte	recruitment	and	organization	of	nascent	vessels	(83).			
2.1.3		 Angs/Tie	signaling	
















Ang1/Tie2	signaling	induces	the	expression	of	heparin-binding	epidermal	growth	factor-like	growth	factor	(HB-EGF),	which	stimulates	mural	migration	though	epidermal	growth	factor	receptors	(EGFRs)	(97).	In	contrast,	during	active	angiogenesis,	Ang2	released	from	Weibel-Palade	bodies	acts	as	a	destabilizing	 factor	 in	an	 autocrine	way.	Ang2	competes	with	Ang1	 for	Tie2	binding	and	does	not	induce	signal	transduction.	This	competition	results	in	a	reduction	in	pericyte	coverage	and	an	increase	in	permeability	and	tip	cells	begin	to	spout	(Fig.	8).	Recent	studies	have	also	demonstrated	that	pericytes	express	Tie2	receptors.	Therefore,	Ang1	 expressed	 by	 pericytes	 acts	 autocrine	 on	 pericytes	 and	 contributes	 to	 vascular	maturation.	On	the	other	hand,	Ang2	released	by	endothelial	cells	binds	Tie2	pericytes	and	favors	vessel	destabilization	directly	on	pericytes	(98).										
	




































vasculatures	while	 ALK	 5	 signaling	 promotes	 cell	 quiescence	 and	 vessel	 stabilization	(68).	
2.1.6	 Ephrins	and	Eph	receptors	signaling	The	erythropoietin-producing	hepatocellular	(Eph)	receptor	family	is	the	largest	class	of	tyrosine	kinase	receptors	in	mammals.	Ephs	have	an	extracellular	domain	consisting	of	a	highly-conserved	N-terminal	ligand-binding	domain,	a	cysteine-rich	region	composed	of	an	epidermal	growth	factor	(EGF)-like	domain,	and	two	fibronectin	type	III	motifs	(FN	III)	(121).	The	intracellular	domain	contains	tyrosine	kinases,	sterile-α	motifs	(SAM)	and	PDZ-binding	motif	which	promote	oligomerization	of	 the	 receptors	 (Fig.	10)	 (122).	 In	humans,	 there	 are	 nine	 EphA	 receptors	which	 are	 attached	 to	 the	 cell	 surface	with	 a	glycosylphosphatidynositol	(GPI)	and	five	Eph	type	B	receptors,	which	are	characterized	by	a	shot	cytoplasmic	region.	The	ligands	are	also	categorized	into	classes	A	and	B	and	into	five	subclass-A	ephrin	ligands	and	five	ephrin-B	ligands	(123).	Eph	type	B	receptors	bind	ephrin	ligands	and	form	the	subclass	B	type,	while	Eph-A	interacts	with	ephrin	type	A,	with	some	exceptions.	Eph	receptors	and	ephrin	ligands	are	both	able	to	transduce	a	signaling	cascade	upon	interaction.	Eph-activated	signaling	is	called	forward,	and	ephrin-activated	signaling	is	called	reverse	(Fig.	10).	Another	level	of	complexity	of	Eph/ephrin	signaling	 is	 the	 fact	 that	 interactions	 between	 Ephs	 and	 ephrins	 can	 occur	






	 Eph	 receptors	 and	 their	 ephrin	 ligands	 control	 several	 cell-cell	 interactions,	including	those	of	vascular	endothelial	cells	and	epithelial	and	stem	cells.	They	also	have	vital	 roles	 in	 bone	 mineral	 metabolism	 and	 the	 immune	 system.	 Veins	 and	 arteries	differentially	 express	 the	members	 of	 the	 Eph	 family.	 EphrinB2	 is	 an	 arterial	marker	while	EphB4	is	expressed	in	veins	(126).	EphB4	and	ephrinB2	are	crucial	 for	vascular	remodeling	of	primitive	capillary	networks	into	distinct	arteries	and	veins.	Mutations	of	ephrinB2	and	EphB4	are	caused	embryonic	lethality,	suggesting	that	both	molecules	are	essential	 during	 the	 remodeling	 of	 the	 primary	 vascular	 plexus	 (127).	 Moreover,	endothelial-specific	knockout	of	Efnb2	cause	embryo	death	due	to	a	complete	arrest	of	angiogenesis	(128).	However,	pericytes	and	vascular	smooth	muscle	cells	also	express	ephrinb2.	Deletion	of	ephrinB2	in	pericytes	and	in	smooth	muscle	cells	resulted	in	diffuse	tissue	 edema,	 hemorrhaging	 and	 perinatal	 death	 of	 the	 mice	 (129).	Furthermore,	activation	of	EphB4	in	mural	cells	reduced	their	ability	to	migrate,	suggesting	that	EphB4	signaling	 in	 pericytes	 may	 favor	 their	 attachment	 to	 the	 endothelial	 cells,	 therefore	stabilizing	the	vessel	wall	(130).	





2.2 Role	of	Sema3A	in	Angiogenesis	and	Stabilization	Semaphorins	are	a	family	of	secreted	and	transmembrane	proteins,	originally	identified	as	 axonal	 guidance	modulators,	 which	 have	 been	 shown	 to	 signal	 through	 two	main	receptor	 families:	plexins	and	Neuropilins	(NPs)	(131).	Semaphorins	are	grouped	 into	eight	major	classes	on	the	basis	of	their	sequence	and	overall	structure	characteristics.	Furthermore,	all	 the	members	of	 this	 family	have	a	conserved	extracellular	domain	of	500	amino	acids	known	as	the	semaphorin	domain,	which	is	a	key	component	through	which	semaphorins	mediate	their	effects	(Fig.	11)	(132).	Class-1	and	class-2	semaphorins	are	found	in	invertebrates,	while	classes	3	to	7	are	present	only	in	vertebrates.	Moreover,	classes	1,	4,	5	and	6	are	membrane-bound	proteins,	while	classes	2	and	3	are	 instead	secreted.	 Class-7	 semaphorins	 are	 glycosylphosphatidylinositol	 (GPI)-linked	 proteins	(133).	 This	 family	 of	 proteins	 is	 predominantly	 expressed	 during	development	 in	 the	nervous	system;	however,	they	are	also	expressed	in	several	tissue	and	organ	systems	including	 the	 cardiovascular,	 endocrine,	 gastrointestinal,	 hepatic,	 immune,	musculoskeletal,	renal,	reproductive	and	respiratory	systems	(132,	134).	In	particular,	class-3	semaphorins	(Sema3)	have	been	shown	to	play	a	crucial	role	in	cardiovascular	development	and	vascular	maturation.			





functionally	 active	 as	 dimers;	 the	 sema	 domain,	 the	 Ig	 domain	 and	 the	 formation	 of	disulfide	bridges	at	the	basic	tail	are	essential	for	protein	dimerization.	Moreover,	the	C-terminal	pro-peptide	undergoes	proteolytic	cleavage	by	furine-like	proteases	in	order	to	stabilize	 the	dimers	(136,	137).	Apart	 from	Sema3E,	class-3	semaphorins	 	require	the	formation	of	holoreceptor	complexes	(which	comprise	plexin	and	neuropilin	proteins)	to	exert	 the	 majority	 of	 their	 effects	 (Fig.	 11).	 Neuropilins	 mediate	 Sema3	 signaling	 in	collaboration	with	signal	transduction	receptors,	like	plexins	and	cell	adhesion	molecules	(CAMS)	(138).											
	 Plexins	are	a	family	of	transmembrane	molecules	divided	into	four	classes,	A	to	D.	The	extracellular	domain	of	plexins	is	a	sema	domain	which	mediates	binding	with	Sema3	dimers	(Fig.	11).	The	intracellular	region	contains	a	guanosine	triphodphstase	(GTPase)-





activating	 protein	 (GAP)	 homology	 domain.	 Sema3/NRP/plexin	 signal	 transduction	 is	still	 poorly	 understood.	 Actually,	 the	 best-described	 semaphorin	 signal	 cascades	 are	those	used	for	axon	guidance	(132).	There	is	a	growing	consensus	that	several	class-3	semaphorins,	such	as	Sema3A	and	Sema3E,	are	involved	in	physiological	and	pathological	angiogenesis.		





Sema3A	 restored	 with	 an	 adeno-associated	 virus	 resulted	 in	 a	 decrease	 in	 tumor	angiogenesis	 and	 tumor	 growth.	 Significantly,	 long-term	 expression	 of	 Sema3A	 in	 the	tumor	 model	 strongly	 improved	 pericyte	 coverage	 of	 tumor-induced	 blood	 vessels,	therefore	 normalizing	 tumor-induced	 angiogenesis.	 They	 observed	 that	 Sema3A	expression	 is	 an	 inhibitor	 of	 tumor	 angiogenesis;	 however,	 it	 can	 favor	 vascular	stabilization	by	increasing	pericyte	recruitment	(146).	Nevertheless,	the	mechanisms	of	Sema3A-mediated	perivascular	cell	recruitment	to	tumor	vessels	remains	to	be	elucidate.	Recently,	it	has	been	shown	that	Sema3A/NP1	signaling	influences	arterial	formation	and	lymphatic	vessel	maturation	via	regulating	pericyte/smooth	muscle	cell	coverage	(147,	148).		





and	the	resultant	failure	to	retain	CXCR4+	cells	leads	to	inhibition	of	angiogenesis	(151,	152).		 Moreover,	 Zacchigna	 et	 al.	 have	 demonstrated	 the	 presence	 of	 a	 population	 of	bone	 marrow-derived	 cells	 recruited	 by	 NP1	 receptors	 at	 the	 site	 of	 VEGF-induced	angiogenesis.	These	infiltrating	cells	are	CD11b+	and	they	express	the	VEGF	and	Sema3a	co-receptor	NP1.	They	are	therefore	named	NP1-expressing	mononuclear	(NEM)	cells.	NEM	are	not	arteriogenic	and	they	are	not	incorporated	in	the	newly-formed	vasculature.	However,	 they	 favor	 arterial	maturation	 through	 the	 secretion	 of	 different	 paracrine	factors—notably	 Ang1,	 TGFβ	 and	 PBGF-BB.	 Their	 paracrine	 effect	 results	 in	 the	activation	and	proliferation	of	smooth	muscle	cells	and	pericytes	(147).	Among	myeloid	cells,	Tie2-expressing	monocytes	(TEMs),	which	represent	2%	of	circulating	monocytes,	play	a	crucial	role	during	tumor	angiogenesis.	TEMs	are	recruited	in	the	tumor	through	Ang2,	where	they	secrete	paracrine	 factors	such	as	VEGF,	MMP9,	COX2	and	Wnt5A	to	promote	tumor	angiogenesis.	Depletion	of	TEMs	impairs	tumor	growth	and	angiogenesis	(153).		


















Therapeutic	angiogenesis	aims	to	stimulate	the	formation	of	new	blood	vessels	from	a	preexisting	vasculature	 to	 treat	 ischemic	diseases.	Delivery	of	 angiogenic	 factor	using	genes,	 proteins	 and	 cells	 have	 shown	 a	 certain	 efficiency	 in	 animal	models.	However,	clinical	angiogenesis	trials	have	proved	challenging	for	demonstrating	positive	results	in	patients	 (155).	 Various	 reasons	 have	 been	 considered	 for	 the	 failure	 of	 clinical	 trials,	ranging	 from	poor	gene	transfer	technology	to	short	duration	of	 transgene	expression	and	a	 lack	 in	persistency	of	vessels	 induced	by	therapy	(156).	 Ischemic	diseases	are	a	group	of	cardiovascular	diseases	caused	by	a	decrease	in	oxygen	supply	to	the	tissues.	These	 diseases	 can	 occur	 in	 the	 heart	 (coronary	 heart	 disease),	 in	 the	 brain	(cerebrovascular	disease)	and	in	the	peripheral	limbs	(peripheral	artery	disease)	(157).	Ischemic	disease	represents	one	of	the	main	heath	care	issues	worldwide	that	continues	to	be	the	leading	cause	of	morbidity	and	mortality	(158).		





composed	of	a	growing	mass	of	lipids	(mainly	cholesterol)	and	connective	tissue.	With	the	progression	of	the	disease,	the	fibrotic	plaques	accumulate	and	grow,	causing	stenosis	of	 the	artery	or	complete	occlusion.	Eventually,	rupture	of	atherosclerotic	plaques	can	result	in	myocardial	infarction	and	stroke	or	acute	leg	ischemia	(160).	Peripheral	artery	disease	affects	more	the	13%	of	 the	population	of	Western	countries,	usually	 in	 those	who	are	more	than	50	years	old.	The	major	risk	factors	associated	with	PAD	are	smoking,	diabetes,	 advancing	age,	hypertension	and	dyslipidemia.	Most	patients	with	PAD	have	mild	or	no	symptoms;	however,	some	people	experience	aching	or	burning	muscles	when	walking	 (claudication).	PAD	can	progress	to	a	more	severe	 form	over	 time,	 leading	 to	resting	pain	and	even	tissue	loss	(critical	limb	ischemia)	(161).	The	current	treatments	for	PAD	include	the	reduction	of	risk	factors	including	tobacco	cessation,	the	adoption	of	a	healthy	diet	and	exercise	and	antiplatelet	medication	therapy.	Moreover,	patients	can	undergo	 invasive	 revascularization	 procedures	 such	 as	 angioplasty,	 artery	 bypass	grafting	 and	 stenting.	 Despite	 advances	 in	 these	 treatments,	 however,	 up	 to	 30%	 of	patients	 with	 PAD	 cannot	 be	 treated	 due	 to	 peri-operative	 risk	 factors	 or	 patient	comorbidities.	 In	 addition,	 some	patients	 can	 develop	 restenosis	 following	 treatment,	resulting	 in	a	diminished	quality	of	 life.	Therefore,	 there	 is	 currently	a	push	 for	novel	therapeutic	 alternatives	 to	 improve	 arteriogenesis	 (collateral	 formation)	 and/or	angiogenesis	(capillary	formation)	in	affected	patients	(157).		















encouraging	results	from	preclinical	studies,	clinical	trials	using	angiogenic	factors	did	not	 demonstrate	 a	 successful	 therapeutic	 efficacy	 in	 patients	 with	 peripheral	 artery	disease.		There	are	many	factors	that	are	likely	responsible	for	these	unsuccessful	results.	First,	 an	 ideal	model	of	peripheral	 artery	disease	 is	not	 currently	available.	There	are	several	differences	between	preclinical	models	and	patients.	Clinical	manifestations	 in	humans	are	heterogeneous	and	patients’	comorbidities	can	influence	the	severity	of	the	disease	 and	 the	 responsiveness	 to	 the	 ischemic	 insult.	 Thus	 far,	 none	 of	 the	 existing	preclinical	models	have	reproduced	chronic	ischemia,	as	normal	reperfusion	comes	by	two	and	three	weeks	in	many	mouse	strains.	Therefore,	angiogenic	therapies	tested	in	preclinical	 animal	models	have	most	 likely	 led	 to	excessively-optimistic	results	which	have	 not	 been	 observed	 in	 patients	 (157,	 164).	 Moreover,	 over-dilated	 non-stable	induced	vessels	and	low	and	short-time	transgene	expression	are	also	possible	reasons	for	potential	 failure	of	clinical	 trials.	Patient	selection	may	affect	 the	results	of	clinical	trials.	 Presumably,	 only	 a	 subgroup	 of	 PAD	 patients	 might	 benefit	 from	 therapeutic	vascular	growth.	Others	with	critical	limb	ischemia	actually	cannot	be	revascularized,	as	a	significant	number	of	new	vessels	and	collateral	arteries	would	be	expected	to	see	a	proper	 improvement	 in	 these	 patients.	 Consequently,	 future	 clinical	 trials	 should	necessarily	identify	patient	subgroups	which	can	respond	positively	to	treatments	and	develop	new	biomarkers	to	drastically	improve	therapeutic	angiogenic	treatments	(170).		















new	strategies	 for	modulating	 the	 timing	and	dosage	of	 the	growth	 factor	 in	order	 to	increase	the	safety	of	VEGF	gene	delivery	by	enabling	short-term	expression.							.					
	
3.4 PDGF-B	angiogenic	normalization	effects	Targeting	the	process	of	vascular	maturation	 is	a	potential	strategy	 for	modulating	or	balancing	VEGF-induced	angiogenesis	in	order	to	overcome	VEGF	limitations	(152).	The	acquisition	of	a	proper	pericyte	coverage	by	newly-formed	blood	vessels	 is	crucial	 for	vessel	 survival,	 maturation	 and	 stabilization	 (66).	 Among	 the	 factors	 regulating	 the	interplay	between	endothelial	cells	and	pericytes,	PDGF-BB	has	a	primary	role,	as	it	is	responsible	 for	 the	 recruitment	 of	 mural	 cells	 during	 the	 angiogenic	 process.	 Dual	delivery	of	recombinant	VEGF	and	PDGF-BB	from	a	polymer	scaffold	promotes	a	stable	and	dense	vasculature	when	compared	with	VEGF	alone.	The	 latter	 induces	 immature	
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IV. Aim	of	the	thesis	
Peripheral	artery	disease	(PAD)	is	a	chronic	condition	characterized	by	narrowed	arteries	and	decreased	blood	supply	in	the	affected	tissues.	The	disease	mainly	affects	the	lower	 limbs.	 It	 manifests	 clinically	 as	 limb	 claudication	 in	 the	 early	 stages	 and	 can	progress	to	a	more	severe	form	characterized	by	rest	pain	and	tissue	loss	(critical	limb	ischemia)	 (1).	 Morbidity	 and	 mortality	 is	 high	 amongst	 individuals	 affected	 by	 the	disease.	 Although	 lifestyle	 changes	 and	medical	 therapies	 have	 shown	 some	 efficacy,	surgical	and	minimally-invasive	revascularization	are	still	the	mainstays	of	treatment	(2).	However,	current	therapies	for	PAD	are	not	suitable	for	all	patients.	With	the	advent	of	gene,	molecular	and	biotechnological	therapies,	new	strategies	could	be	investigated	in	order	 to	 promote	 the	 formation	 of	 new	 collateral	 arteries	 (arterogenesis)	 and/or	capillaries	(angiogenesis)	and	to	restore	blood	flow	(3).		Vascular	endothelial	growth	factor	(VEGF)	plays	a	crucial	role	in	the	angiogenic	process.	 Consequently,	 it	 is	 widely	 used	 in	 clinical	 trials	 to	 induce	 therapeutic	angiogenesis.	 VEGF	 delivery	 in	 ischemic	 tissues	 has	 been	 associated	 with	 improved	collateral	 artery	 development,	 which	 is	 a	 key	 process	 for	 functional	 recovery	 (4).	Nevertheless,	initial	positive	results	from	clinical	trials	with	VEGF	did	not	demonstrate	any	long-term	functional	improvement.	Additionally,	the	efficacy	of	VEGF	therapy	has	not	been	confirmed	in	placebo-controlled	phase	II	studies.	The	major	obstacle	of	VEGF	gene	therapy	appears	to	be	its	narrow	therapeutic	window.	While	low	doses	are	not	sufficient	to	induce	functional	improvement,	levels	above	a	specific	threshold	are	associated	with	aberrant	vascular	structures	(5).	There	is	thus	the	need	to	precisely	control	the	dose	of	VEGF	delivered	in	vivo.	Several	studies	have	focused	on	the	development	of	alternative	
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strategies	for	better	controlling	the	effects	of	VEGF	doses	in	order	to	induce	normal	and	functional	angiogenesis.	Further,	short-term	expression	of	these	potent	growth	factors	is	desirable	 for	 ensuring	 safe	 angiogenesis.	 However,	 it	 is	 inefficient	 for	 achieving	persistent	 and	 stable	 vessels,	 as	 four	 weeks	 of	 sustained	 expression	 are	 required	 to	achieve	vascular	stabilization	(6).		Notably,	we	previously	found	that	co-expression	of	VEGF	and	PDGF-BB	at	a	fixed	ratio	can	prevent	the	formation	of	aberrant	structures	by	high	and	uncontrolled	VEGF,	suggesting	a	safe	strategy	for	inducing	therapeutic	angiogenesis	with	direct	gene	therapy	(7).	 Moreover,	 we	 recently	 found	 that	 increasing	 VEGF	 doses	 impairs	 vascular	stabilization	 without	 affecting	 pericyte	 recruitment.	 Rather,	 it	 directly	 inhibits	endothelial	 expression	 of	 Sema3A	 and	 leads	 to	 impaired	 Neuropilin-expressing	monocyte	 recruitment	 and	 TGF-β1	 signaling	 in	 the	 endothelium.	 PDGF-BB	 has	 been	shown	 to	 normalize	 aberrant	 angiogenesis	 from	 excessive	VEGF	doses	 by	 stimulating	pericyte	 recruitment.	 However,	 it	 is	 unknown	 whether	 PDGF-BB	may	 also	 affect	 the	stabilization	 kinetics	 of	 VEGF-	 induced	 angiogenesis.	 As	 the	 co-delivery	 of	 PDGF-BB	normalizes	VEGF-induced	vessel	growth,	we	will	investigate	whether	PDGF-BB	may	also	modulate	the	stabilization	of	VEGF-induced	angiogenesis	and	its	underlying	mechanisms.									
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V. A	 pericyte-independent	 role	 for	 PDGF-BB	 to	
accelerate	 vascular	 stabilization	by	 stimulating	 the	
Sema3A/NP1+	Monocyte	axis	





















Aflibercept	treatment		Mice	were	 injected	 i.p.	with	Aflibercept	 (25mg/Kg;	 100ul)	 in	 PBS	or	with	 the	 vehicle	(100ul	 of	 PBS)	 4	 and	 2	 days	 before	 tissue	 harvesting.	 At	 14	 and	 21	 days	 after	 VEGF	depletion	in	vivo,	muscles	were	harvested	and	processed	to	examine	vessels	stabilization.		
Anti-NRP1A	antibody	treatment	Mice	were	treated	systematically	by	i.p.	injection	with	an	anti-NRP1A	blocking	antibody	(YW64.3,	 Genentech	 Inc.,	 South	 San	 Francisco,	 CA,	 USA)	 (14)	in	 PBS	 with	 0.5%	 BSA	(10mg/kg)	or	with	an	IgG2A	(10mg/kg)	as	control.	Animals	were	treated	at	the	time	of	myoblast	implantation	(day	0)	and	every	3	days	till	the	final	time	point,	according	to	the	previously	published	treatment	schedule	(15).		
Tissue	staining		Mice	 were	 anesthetized	 with	 ketamine	 (100mg/kg)	 and	 Xylazine	 (10mg/kg)	 and	sacrificed	by	intravascular	perfusion	with	1%	paraformaldehyde	in	PBS	pH7.4.	Tibialis	





Germany)	at	1:200;	rat	monoclonal	anti-CD11b	(clone	M1/70,	Abcam,	Cambridge,	UK)	at	1:100;	 rabbit	 polyclonal	 anti-p-SMAD2/3	 (Santa	 Cruz	 Biotechnology,	 Santa	 Cruz,	 CA,	USA)	at	1:100;	rabbit	polyclonal	anti-Ki67	(Abcam,	Cambridge,	UK)	at	1:100	and	rabbit	polyclonal	 anti-Sema3A	 (Abcam)	 at	 1:50.	 Fluorescently	 labeled	 secondary	 antibodies	(Invitrogen,	Basel,	Switzerland)	were	used	at	1:200.	The	Sema3A	primary	antibody	was	detected	 with	 a	 peroxidase-labeled	 anti-rabbit	 secondary	 antibody.	 The	 first	chromogenic	 signal	 was	 developed	 with	 3,3′-diaminobenzidinetetrahydrochloride	(Sigma).	To	 study	vessel	perfusion	 in	vivo,	mice	were	 injected	with	100	µl	 (1g/ml)	of	FITC-labeled	 Lycopersicon	 esculentum	 lectin	 (Vector	 Laboratories	 Inc.,	 U.S.A)	 into	 the	femoral	vein	and	allowed	to	circulate	for	4	minutes	prior	intravascular	perfusion	(7).	
	
VEGF164	and	PDGF-BB	ELISA	measurements	






















	 Pericyte	coverage	was	quantified	after	immunostaining	for	endothelium	(CD31)	and	pericytes	(NG2)	from	5-10	fields	per	muscles	(n=3).	Images	were	taken	with	a	40X	objective	 on	 a	 Carl	 Zeiss	 LSM710	 3-laser	 scanning	 confocal	 microscope	 (Carl	 Zeiss,	Feldbach,	 Switzerland).	 Briefly,	 the	 volume	 of	 CD31	 and	 NG2	 positive	 areas	 were	measured	 with	 Imaris	 software	 (Bitplane	 AG,	 Zurich,	 Switzerland)	 and	 pericyte	maturation	index	was	calculated	as	a	ratio	between	the	two	values	obtained.		
	








Quantitative	Real-Time	PCR	For	RNA	extraction	 from	total	muscles,	mice	were	previously	 injected	with	transgenic	myoblasts	and	muscles	were	freshly	harvested	and	then	disrupted	using	a	Qiagen	Tissue	Lyser	 (Qiagen)	 in	 1	ml	 of	 Tri	 Reagent	 solution	 (Invitrogen).	 The	 RNA	 was	 extracted	according	 to	manufacturer’s	 instructions.	 RNA	 from	 in	 vitro	 endothelial	 cells	or	 FACS	sorted	 cell	was	extracted	with	RNAeasy	Mini	Kit	 (Qiagen).	The	 total	RNA	was	 reverse	transcribed	into	cDNA	with	an	Omniscript	Reverse	Transcription	kit	(Qiagen)	at	37°C	for	60	minutes.	The	quantitative	Real-Time	PCR	was	performed	on	an	ABI	7300	Real-Time	PCR	 system	 (Applied	 Biosystems).	 The	 commercial	 TaqMan	 gene	 expression	 assay	(AppliedBiosystems)	was	 used	 to	 determine	 the	 expression	 of	 genes	 of	 interest.	 The	cycling	parameters	were:	50°C	for	2	minutes,	followed	by	95°C	for	10	minutes	and	40	cycles	of	denaturing	at	95°C	for	15	seconds	an	at	last	annealing/	extension	at	60°C	for	1	minute.	Reactions	were	performed	two	or	three	times	for	each	template,	averaged	and	normalized	to	expression	of	the	GAPDH	housekeeping	gene.		





Subsequently,	 cells	 were	 collected	 after	 stimulation	 and	 RNA	 extraction,	 reverse	transcription	and	qRT-PCR	was	performed	as	explained	before.	To	quantify	VEGFR2	in	
vitro	 Phosphorylation,	 HDMEC	 were	 seeded	 in	 12-well	 plate	 (0.1x106cells/well)	 and	starved	 overnight.	 Cells	 were	 then	 stimulated	 with	 hVEGF	 (40ng/ml)	 alone	 or	 in	combination	with	hPDGF-BB	(10ng/ml)	for	5	min	and	then	lysed	with	Lysis	Buffer	(Cell	Signaling	Technology)	 supplemented	with	 1	mM	PMSF	 (Sigma)	 for	 5	min	 on	 ice.	 Cell	lysates	were	assayed	 for	VEGFR2	phosphorylation	of	VEGFR2	with	Phospho-VEGFR-2	(Tyr1175)	Sandwich	ELISA	(Cell	Signaling	Technology)	as	described	in	the	manufacturer	protocol.		
	

























Vascular	stabilization	kinetics	depend	on	PDGF-BB	dose	In	order	to	assess	the	role	of	PDGF	-BB	dose	on	the	kinetics	of	vessels	stabilization,	we	used	a	previously	 characterized	pool	of	monoclonal	myoblast	populations,	 genetically	modified	 to	 express	 specific	 doses	 of	 VEGF	 and	 PDGF-BB	 at	 a	 fixed	 ratio	 of	 4:1	 (VIP	clones),	 to	 ensure	 homogeneous	microenvironment	 levels	 (17).	We	 selected	 3	 clonal	populations	based	on	their	in	vitro	expression	of	the	two	growth	factors	at	the	fixed	ratio:	low	 (VEGF	 »10ng/106	 cells/day	 –	 PDGFBB	 »2.5ng/106	 cells/day),	 medium	 (VEGF	












Stabilization	 kinetics	 does	 not	 correlate	 with	 differential	 pericyte	 coverage	 or	


















Increasing	 PDGF-BB	 levels	 up-regulate	 Sema3a	 and	 TGF-b1	 expression	 with	





muscles	 and	 the	 expression	 of	 the	 maturation	 factors	 was	 quantified	 after	 7	 days.	Interestingly,	increasing	doses	of	PDGF-BB	alone	caused	an	upregulation	of	Sema3a	and	
Tgfb1	 expression	 in	 total	muscles	 even	 in	 the	 absence	 of	 VEGF	 (Fig.4B),	 suggesting	 a	direct	 regulation	of	Sema3a	expression	by	PDGF-BB.	Gene	expression	data	of	Sema3a	expression	in	the	VIP	conditions	were	confirmed	by	immunostaining	for	Sema3A	protein,	which	 showed	 a	 progressive	 increase	 of	 Sema3A	 in	 the	 tissues	 (Fig.4C-H).	 All	 the	implanted	myoblast	populations	(VIP	and	P	clones)	expressed	low	levels	of	Sema3A	in	


























Increasing	VEGF	and	PDGF-BB	doses	 promote	 endothelium	quiescence	 via	TGF-β1	
pathway		TGF-β1	 is	 known	 to	 regulate	 endothelium	 state	 by	 differentially	 activating	 ALK1	 and	ALK5	 receptors	 (20).	 TGFβ/ALK1	 signaling	 induces	 Smad1/5	 phosphorylation	 and	stimulates	EC	proliferation	and	migration	during	tube	formation	(21).	In	contrast,	TGF-β/ALK5	signaling	stimulates	Smad2/3	pathway,	which	has	been	shown	to	mediate	vessel	maturation	 and	 stability	 through	 inhibition	 of	 EC	 proliferation	 and	 migration	 (20).	Therefore,	 we	 sought	 to	 assess	 whether	 TGF-β	 signaling	 on	 endothelial	 cells	 was	differentially	 regulated	upon	stimulation	with	 increasing	doses	of	VEGF	and	PDGF-BB	and	increased	TGF-b1	expression	in	tissue.	As	shown	in	Fig.6	(A-I)	immunofluorescence	staining	 of	 phosphorylated	 Smad2/3	 complex	 was	 detectable	 in	 EC	 nuclei	 only	 in	presence	of	high	levels	of	VEGF	and	PDGF-BB,	which	cause	the	greater	increase	in	TGF-





and	 suppression	 of	 endothelial	 proliferation,	 i.e.	 the	 processes	 that	 favor	 vessel	stabilization.	 																	
		
Figure	 6.	 Increasing	 doses	 of	 VEGF+PDGF-BB	 promote	 endothelial	 cells	 quiescence	 that	 mediates	 vessel	










Treatment	 with	 the	 NP1A	 antibody	 significantly	 decreased	 the	 fraction	 of	 persistent	vessels	 in	 both	 cases,	 by	 60%	 with	 VIP	 High	 and	 by	 30%	 with	 V	 Low	 (Fig.	 7J).	Interestingly,	 the	 vessel	 fraction	 that	 could	 stabilize	 independently	 of	 Sema3A/NP-1	signaling	was	the	same	in	both	conditions,	accounting	for	about	30%	of	newly	induced	angiogenesis.	These	results	demonstrate	that	Sema3A/Neuropilin-1	signaling	on	NEM	is	required	for	the	accelerated	vessel	stabilization	induced	by	PDGF-BB	co-delivery.															



















PDGF-BB	maintains	endothelial	Sema3a	expression	despite	high	VEGF		We	have	recently	found	that	endothelial	cells	are	the	main	source	of	Sema3A	production	during	VEGF-induced	angiogenesis	and	that	endothelial	Sema3A	is	down-regulated	by	increasing	 VEGF	 doses	 (7).	 To	 investigate	 the	 effect	 of	 PDGF-BB	 co-delivery	 on	endothelial	Sema3A,	its	expression	was	measured	from	endothelial	cells	isolated	ex-vivo	from	tissues	exposed	to	different	VIP	doses.	FACS-sorted	CD31+	cells	expressed	similar	levels	of	Sema3a	 in	 all	 conditions	 (Fig.	9A).	Therefore,	 the	 robust	 increase	 in	Sema3A	detected	 in	 the	 VIP	 High	 tissues	 was	 not	 observed	 in	 CD31+	 cells,	 suggesting	 that	endothelium	might	not	be	the	only	source	of	Sema3A	in	these	conditions.	However,	 it	should	 also	 be	 noticed	 that	 the	 loss	 of	 endothelial	 Sema3a	 expression	 that	would	 be	expected	 in	 the	 presence	 of	 increasing	 VEGF	 doses	 was	 prevented	 by	 PDGF-BB	 co-delivery,	 suggesting	 that	 PDGF-BB	 may	 also	 regulate	 Sema3A	 expression	 directly	 in	endothelial	cells.		In	 order	 to	 investigate	 this	 hypothesis,	 Human	 Dermal	 Microvascular	 Cells	(HDMEC)	were	stimulated	 for	24	hours	 in	vitro	with	two	different	high	doses	of	VEGF	alone	(10	and	40	ng/ml,	respectively),	or	together	with	PDGF-BB	at	a	fixed	1:4	ratio	(2.5	and	 10	 ng/ml	 of	 PDGF-BB,	 respectively),	 or	with	 the	 same	 doses	 of	 PDGF-BB	 alone.	





These	 data	 suggest	 that	 VEGF	 and	PDGF-BB	 exert	 an	 opposite	 regulation	 on	 Sema3A	expression	 in	 endothelial	 cells.	 In	 order	 to	 start	 investigating	 the	 mechanism	 of	 this	interaction,	we	asked	whether	PDGF-BB	may	interfere	with	VEGF-R2	activation	by	VEGF.	HDMEC	were	treated	with	40	ng/ml	of	VEGF	alone	or	together	with	10	ng/ml	of	PDGF-BB	and	VEGF-R2	phosphorylation	at	the	key	tyrosine	residue	Tyr1175	was	quantified	by	ELISA.	The	results	(Fig.	9C)	show	that	PDGF-BB	co-delivery	did	not	interfere	with	VEGF-R2	 phosphorylation	 by	 VEGF,	 suggesting	 that	 VEGF	 and	 PDGF-BB	 might	 regulate	endothelial	Sema3A	expression	indirectly	through	downstream	signaling	cascades.												
		































































expression	 by	 endothelial	 cells.	 However,	 VEGF	 and	 PDGF-BB	 co-stimulation	 of	endothelial	 cells	 in	 vitro	 did	 not	 interfere	 with	 VEGF-dependent	 VEGFR2	phosphorylation,	although	it	can’t	be	excluded	that	PDGF-BB	may	act	through	VEGFR2	(Fig.	9C).	Recently,	Mamer	and	coworkers	identified	and	measured	novel	PDGFs	to	VEGF-R	interactions	utilizing	surface	plasmon	resonance.	They	proved	that	PDGF-BB	can	bind	VEGFR2	with	a	KD=40	nM,	and	this	cross-family	interaction	can	expand	the	role	of	these	growth	factors	in	angiogenesis.	In	a	cross-family	signaling	system,	ligands	can	compete	to	bind	the	same	receptors	and	ligand	concentration	as	well	as	ligand-receptor	binding	kinetics	 may	 determine	 which	 ligand(s)	 is	 dominating	 the	 signaling	 (34).	 Moreover,	PDGF-BB	can	physically	interact	with	NP1	(35).	Thus,	additional	in	vitro	assays	such	as	blocking	of	VEGFR2,	PDGFRa	or	NP1	after	stimulation	with	PDGF-BB	are	necessary	to	better	elucidate	Sema3A	regulation	of	expression	by	endothelial	cells.	
Ex-vivo	endothelial	Sema3a	expression	data	and	fluorescent	in	situ	hybridization	for	Sema3A	revealed	that	endothelial	cells	are	not	the	only	source	of	the	glycoprotein.	In	fact,	 increasing	 doses	 of	 VEGF	 and	 PDGF-BB	 promoted	 Sema3A	 expression	 by	 a	population	 of	 non-endothelial	 cells	 (NEC)	 (Fig.	 10).	 Further,	 FISH	 data	 showed	 that	





favors	 vessels	 stabilization,	 while	 further	 stimulating	 Sema3A	 production	 by	endothelium	 in	a	pro-stabilization	positive	 feedback	 loop.	PDGF-BB	plays	an	essential	role	 in	 pericyte	 recruitment	 and	 vessel	maturation.	 However,	 here	we	 found	 a	 novel	pericyte-independent	 function	 of	 PDGF-BB	 in	 promoting	 vessel	 stabilization	 by	stimulating	Sema3A	expression	to	start	the	NEM/TGF-b1/Sema3A	stabilizing	feedback	loop	 previously	 described.	 Therefore,	 PDGF-BB	 co-delivery	 represents	 a	 promising	strategy	for	therapeutic	angiogenesis	as	it	allows	to	overcome	both	main	limitations	of	VEGF	 delivery:	 1)	 PDGF-BB	 normalizes	 VEGF-induced	 angiogenesis	 expanding	 VEGF	therapeutic	window;	 and	 2)	 it	 accelerates	 vascular	 stabilization	 through	 Sema3A	 up-regulation,	NEM	recruitment	and	TGF-b1	release,	enabling	a	safe	short-term	VEGF	gene	therapy.	
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